Navigation Links
Genesis Biopharma Names David Voyticky to Board of Directors
Date:7/18/2011

LOS ANGELES, July 18, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named David Voyticky to its Board of Directors.  Mr. Voyticky is currently President of Miller Energy Resources (NYSE: MILL), an oil and gas exploration company, and has more than 16 years of experience in corporate finance and merger and acquisition consulting. The Genesis Biopharma Board now consists of 6 members, including 4 independent directors.

"David's experience in guiding high growth companies will help us effectively manage our current opportunities," stated Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma. "In addition, as the Company is poised to be a leader in developing new cancer therapies, David's background and expertise in corporate finance and strategic transactions will play an important role in building long term value."

Previously Mr. Voyticky served as a Vice President at the investment banks Goldman Sachs & Co. and Houlihan Lokey Howard & Zukin, where he advised public and private companies on mergers, acquisitions, divestitures, joint ventures, cross-border transactions, and capital-raising activities. He was also a founding partner in Red Mountain Capital Partners, and a partner in Chapman Capital LLC, an activist hedge fund focused on middle market public companies.

Mr. Voyticky received Juris Doctorate and Master's of Business Administration degrees from the University of Michigan, and also holds a Master's in International Policy and Economics from the Ford School at the University of Michigan.  He received his Bachelor of Arts in Philosophy from Pomona College.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing announcement contains forward-looking statements that can be identified by such terminology as "expects", "hopes", "potential", "suggests", "bodes", "may", "should", "could", or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general.  Forward-looking statements speak only as of the date they are made.  The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenesis Biomedical Announces Additions to Board of Directors
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
6. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
7. Genesis Pharmaceuticals Launches New Corporate Website
8. ThermoGenesis Presentation at Rodman & Renshaw Conference
9. Cardiogenesis Reports Third Quarter 2008 Results
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016  BD (Becton, Dickinson and Company) ... company, today announced the launch of the BD CLiC™ ... Technology (AGBT) Meeting. --> ... research by providing cost effective NGS library preparation with ... high-throughput, fully integrated, next generation sequencing (NGS) library prep ...
(Date:2/12/2016)... Feb. 12, 2016  PTC Therapeutics, Inc. (NASDAQ: ... STRIVE (Strategies to Realize Innovation, Vision and Empowerment) ... STRIVE provides funds to patient advocacy organizations to ... meaningful contributions to the rare disease community by ... future patient advocates. Mary Frances ...
(Date:2/12/2016)... FRANCISCO , February 12, 2016 ... Medicine Efforts by Enabling Scientific Understanding of Complex ... and Rare Diseases --> ... genomic diagnostics in South Asia and a leading provider ... would contribute $10 million to the GenomeAsia 100K ...
(Date:2/11/2016)... ORLANDO, Florida , February 11, 2016 ... Populations and Promote Genetic Understanding to Support Research and Discovery ... consortium, GenomeAsia 100K, today announced an ambitious plan to sequence ... 12 South Asian countries and at least 7 of North ... --> In the first phase, the project will focus ...
Breaking Biology Technology:
(Date:2/11/2016)...  According to new research from Acuity Market ... 200 fingerprint, iris, and eye-vein biometric smartphones have ... names. This includes market leaders Apple, Samsung, Huawei, ... that 600 million biometric smartphones are currently in ... Maxine Most , Acuity Market Intelligence ...
(Date:2/11/2016)... Solutions announces today that its license plate recognition (LPR) cameras ... Lee,s Summit Police Department to improve safety for ... homicide suspect. Kansas City , ... and is home to roughly 100,000 residents. Lee,s ... plate reader system and also leverages Vigilant,s network of commercially ...
(Date:2/10/2016)... February 10, 2016 ... to 2016 iris recognition market report, combined ... is more widely accepted for border control. ... fingerprint and iris recognition technology in a ... avoid purchasing two individual biometrics devices. ...
Breaking Biology News(10 mins):